Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
PARSIPPANY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 31 st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3, 2019. Live audio of the event can be accessed by visiting the ...
PARSIPPANY, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday, November 20, 2019. Live audio of the event can be accessed by visit...
Image source: The Motley Fool. Pacira Pharmaceuticals Inc (NASDAQ: PCRX) Q3 2019 Earnings Call Nov 7, 2019 , 8:30 a.m. ET Operator Continue reading
Pacira BioSciences, Inc. (PCRX) Q3 2019 Results Earnings Conference Call November 7, 2019, 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman and CEO Dr. Richard Scranton - Chief Medical Officer Charlie Reinhardt - Chief Financial Offic...
Pacira Pharmaceuticals (NASDAQ: PCRX ): Q3 Non-GAAP EPS of $0.48 beats by $0.16 ; GAAP EPS of -$0.15 misses by $0.20 . Revenue of $104.7M (+25.5% Y/Y) misses by $0.18M . Press Release More news on: Pacira BioSciences, Inc., Earnings news and commentary, Healthcare stocks news,
-- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain man...
PARSIPPANY, N.J., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, November 7, 2019. Following the release, the company will host a live conferenc...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +21% on end of PB2452 trial . More news on: PhaseBio Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Philip Morris International Inc., Stocks on the move, Read more ...
NEW YORK , Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September 30 . Apollo Global Management Inc. (NYSE: APO) is acquiring Shutterfly in a tra...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
2024-06-23 19:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-13 14:15:06 ET Jefferies analyst issues BUY recommendation for PCRX on June 13, 2024 11:57AM ET. The previous analyst recommendation was Buy. PCRX was trading at $28.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-06-13 14:00:08 ET Glen Santangelo from Jefferies issued a price target of $36.00 for PCRX on 2024-06-13 11:57:00. The adjusted price target was set to $36.00. At the time of the announcement, PCRX was trading at $28.5. The overall price target consensus is at $52.33...